{"id":534112,"date":"2021-09-02T16:13:07","date_gmt":"2021-09-02T20:13:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/"},"modified":"2021-09-02T16:13:07","modified_gmt":"2021-09-02T20:13:07","slug":"arcutis-announces-appointment-of-keith-leonard-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/","title":{"rendered":"Arcutis Announces Appointment of Keith Leonard to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WESTLAKE VILLAGE, Calif., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZdcE1iN1ognrjn_988FU6CNyxZBms9Hii2G5PaQSSLUJCZLOCcYSGrJBQ0a_c7PRYh7F_cBKJcGYVyPHIcwdF6mGOUfFBc-g6rkDxF5-b24=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Arcutis Biotherapeutics, Inc.<\/u><\/a>\u00a0(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Keith R. Leonard Jr. has been appointed to the Arcutis Board of Directors effective September 2, 2021, replacing Ricky Sun, Ph.D., who has decided to step down from the Board for personal reasons.<\/p>\n<p>\u201cWe thank Ricky for his leadership over the past three years,\u201d commented <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JKstKGo7qQJEfRhphlKStD43v2WsjibYu16U8dOfS2LsY60GdezJjPIfFCr-6-UD3ralEbottjtNiY_5eC2_CeR5bUuoxVk2MycqsRPWuJU=\" rel=\"nofollow noopener\" target=\"_blank\">Patrick Heron<\/a>, Chairman of the Arcutis Board of Directors. \u201cHe made significant contributions to Arcutis as the company grew from a start-up to a company with a robust pipeline of novel immuno-dermatology drug candidates on the cusp of its first NDA submission. We wish him all the best in his future endeavors.\u201d<\/p>\n<p>\u201cWe are delighted to welcome Keith to the Arcutis Board,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8dKhP6swAReg33aidSsNYba74h13WNaoOmD_UZuwpoknt9XvlVTaP3cQyAZNCNgv0ciipst8WIQETAqdRAPTcZigrJLBwxptXrclXOVHiVbX1VRPwDCe42oVMv_LWNOv\" rel=\"nofollow noopener\" target=\"_blank\">Frank Watanabe<\/a>, Arcutis\u2019 President and Chief Executive Officer. \u201cKeith adds to the depth of our board with over 25 years of commercial, operational, and international leadership experience. As a sitting chair of a publicly listed biotechnology company, a former CEO of two public biotech companies, and someone who has launched products at both large and emerging biopharmaceutical companies, Keith\u2019s insights will be instrumental as we prepare for our first potential commercial launch of topical roflumilast.\u201d<\/p>\n<p>\u201cI am thrilled to join the Arcutis board at this pivotal time,\u201d said Keith Leonard. \u201cI am impressed with Arcutis\u2019 product candidates and the team\u2019s dedication to providing important and effective solutions for dermatology patients that do not require a tradeoff between safety, efficacy, and tolerability. I look forward to working with the Arcutis management team on its development and commercialization efforts, and to bringing value to patients, physicians, and shareholders.\u201d<\/p>\n<p>Keith Leonard is Chairman of the Board of UNITY Biotechnology, where he served as Chief Executive Officer from 2016 to 2020, and currently serves on the board of robotic surgery pioneer Intuitive Surgical and Spanish biotech SANIFIT S.A.. Previously, Keith served as the Chief Executive Officer of KYTHERA Biopharmaceuticals from its founding in 2005 to its acquisition by Allergan plc in 2015. Before KYTHERA, Keith spent 13 years at Amgen, ultimately as Senior Vice President and General Manager at Amgen Europe, where he ran all commercial operations in 28 countries. Prior to that position, Keith ran Amgen\u2019s manufacturing operations in Europe, established Amgen\u2019s presence in inflammation, served as Head of Information Management, and had leadership roles in sales and marketing, engineering, operations, and finance. Keith has been an Independent Director of Anacor Pharmaceuticals, Affymax, and ARYx Therapeutics, and was a venture partner with ARCH Venture Partners. He holds a Master of Business Administration from The Anderson School of Management, University of California, Los Angeles, a Master of Science in Mechanical Engineering from University of California, Berkeley, a Bachelor of Arts in History from University of Maryland, College Park, and a Bachelor of Science in Engineering from University of California, Los Angeles.<\/p>\n<p><strong>About Arcutis<\/strong><br \/>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis\u2019 dermatology development platform includes a robust pipeline with seven clinical programs for a range of inflammatory dermatological conditions, with our first NDA submission anticipated by the end of 2021 and three more Phase 3 clinical data readouts anticipated over the next 18 months. The company\u2019s lead product candidate, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lh8BuS6BFzLHZJdwNR4t5VvII376Du9h7AvkCi78cw1j-VrfGIRFoeOReVRSACI0AEiRAuCDDehjGNTDqQL2hg==\" rel=\"nofollow noopener\" target=\"_blank\">www.arcutis.com<\/a>\u00a0or follow Arcutis on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PuUxpgw8DKw-SjZnuyxgzYJmlgk2MFJ7CR9ik5If-cyS8u9hR0G3E2BgrVydicqwIdyILmELKcFhR8sjybogZHbqVd6rzWKOkXDRP08LeKk=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8LUh4ef_2jW5juL2vJO1zH0SyHVUIeUqjMJ6p4dX4R7sewEwm_9lZMMscasIXBclZ09RcRsPP8PkKuVK--fBBw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains &#8220;forward-looking&#8221; statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the &#8220;Risk Factors&#8221; section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Media<\/strong>\n      <\/p>\n<p>Amanda Sheldon, Head of Corporate Communications<\/p>\n<p>(805) 418-5006<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XKTdrHBIaBgCZ6YYY6A0ofudi8pdrUsMIg8QD8x1ZxGLQXM2T0hHXIXxo_aisiE6M-P7TmC4L63qUzFY2e-XXp9Hvu14uBrc-8hy8-QvzyU=\" rel=\"nofollow noopener\" target=\"_blank\">asheldon@arcutis.com<\/a>\n      <\/p>\n<p>\n        \n      <\/p>\n<p>\n        <strong>Investors<\/strong>\n      <\/p>\n<p>Eric McIntyre, Head of Investor Relations<\/p>\n<p>(805) 418-5006<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ynmsHNFq7AKRZjEwqQUFdsseE1jI-SLyqNo4MSfdw_wqn4-uFGfzH9St9kEFmcM1CLiwCLc7OmhtpFzWgcjaPfinINFI2l0UEhAeStqR34w=\" rel=\"nofollow noopener\" target=\"_blank\">emcintyre@arcutis.com<\/a>\n      <\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y6GvaM9mXmjjLcThHllivwo0W2E60mYIXfFskgi-pZYW4NenIUaSE5TVeEvG8AqEsNHG2lmKhwkDxyJ3kBcKXlnd2rBQnNEeH7DL1OZpfSMJWa_3rLWFkFx9p5bVytKjpeMifBp7rF_rWSSSUJ-YML-s50hZ85AAyWkxwhp5kynmF93s33I0xXTugUk7oaxZzG6o91kbAoDtiH4NUyUDUs70Z7wRLuk3U2w-jvhR1CT8e3nZs7HAVlK8RqYcLdreqfLO9O_G2pBIv1tlHzaJKQ==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/e14992f0-879a-4428-9247-9ffd730d2ade<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmZjYjExNTctNDIzOC00NDZhLTg5ZTctZWYzZjI0YzVjMTY3LTEyMDU2MDM=\/tiny\/Arcutis-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Keith R. Leonard Jr. has been appointed to the Arcutis Board of Directors effective September 2, 2021, replacing Ricky Sun, Ph.D., who has decided to step down from the Board for personal reasons. \u201cWe thank Ricky for his leadership over the past three years,\u201d commented Patrick Heron, Chairman of the Arcutis Board of Directors. \u201cHe made significant contributions to Arcutis as the company grew from a start-up to a company with a robust pipeline of novel immuno-dermatology drug candidates &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcutis Announces Appointment of Keith Leonard to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534112","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcutis Announces Appointment of Keith Leonard to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcutis Announces Appointment of Keith Leonard to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Keith R. Leonard Jr. has been appointed to the Arcutis Board of Directors effective September 2, 2021, replacing Ricky Sun, Ph.D., who has decided to step down from the Board for personal reasons. \u201cWe thank Ricky for his leadership over the past three years,\u201d commented Patrick Heron, Chairman of the Arcutis Board of Directors. \u201cHe made significant contributions to Arcutis as the company grew from a start-up to a company with a robust pipeline of novel immuno-dermatology drug candidates &hellip; Continue reading &quot;Arcutis Announces Appointment of Keith Leonard to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T20:13:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcutis Announces Appointment of Keith Leonard to Board of Directors\",\"datePublished\":\"2021-09-02T20:13:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/\"},\"wordCount\":874,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/\",\"name\":\"Arcutis Announces Appointment of Keith Leonard to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=\",\"datePublished\":\"2021-09-02T20:13:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcutis Announces Appointment of Keith Leonard to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcutis Announces Appointment of Keith Leonard to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Arcutis Announces Appointment of Keith Leonard to Board of Directors - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Keith R. Leonard Jr. has been appointed to the Arcutis Board of Directors effective September 2, 2021, replacing Ricky Sun, Ph.D., who has decided to step down from the Board for personal reasons. \u201cWe thank Ricky for his leadership over the past three years,\u201d commented Patrick Heron, Chairman of the Arcutis Board of Directors. \u201cHe made significant contributions to Arcutis as the company grew from a start-up to a company with a robust pipeline of novel immuno-dermatology drug candidates &hellip; Continue reading \"Arcutis Announces Appointment of Keith Leonard to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T20:13:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcutis Announces Appointment of Keith Leonard to Board of Directors","datePublished":"2021-09-02T20:13:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/"},"wordCount":874,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/","name":"Arcutis Announces Appointment of Keith Leonard to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=","datePublished":"2021-09-02T20:13:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTczMyM0Mzg1NjcwIzIxOTQwNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcutis Announces Appointment of Keith Leonard to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534112"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534112\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}